340 related articles for article (PubMed ID: 32233400)
1. Small-Molecule Modulators of Toll-like Receptors.
Wang Y; Zhang S; Li H; Wang H; Zhang T; Hutchinson MR; Yin H; Wang X
Acc Chem Res; 2020 May; 53(5):1046-1055. PubMed ID: 32233400
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics.
Wang J; Zhang J; Wang J; Hu X; Ouyang L; Wang Y
J Med Chem; 2023 May; 66(10):6437-6462. PubMed ID: 37163340
[TBL] [Abstract][Full Text] [Related]
3. Targeting Toll-like receptors with small molecule agents.
Wang X; Smith C; Yin H
Chem Soc Rev; 2013 Jun; 42(12):4859-66. PubMed ID: 23503527
[TBL] [Abstract][Full Text] [Related]
4. Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview.
Romerio A; Peri F
Front Immunol; 2020; 11():1210. PubMed ID: 32765484
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.
Li TT; Ogino S; Qian ZR
World J Gastroenterol; 2014 Dec; 20(47):17699-708. PubMed ID: 25548469
[TBL] [Abstract][Full Text] [Related]
6. Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins.
Ippagunta SK; Pollock JA; Sharma N; Lin W; Chen T; Tawaratsumida K; High AA; Min J; Chen Y; Guy RK; Redecke V; Katzenellenbogen JA; Häcker H
Sci Signal; 2018 Aug; 11(543):. PubMed ID: 30108181
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in the development of Toll-like receptor (TLR) antagonists.
Patra MC; Choi S
Expert Opin Ther Pat; 2016 Jun; 26(6):719-30. PubMed ID: 27136061
[TBL] [Abstract][Full Text] [Related]
8. A Novel Small-Molecule Inhibitor of Endosomal TLRs Reduces Inflammation and Alleviates Autoimmune Disease Symptoms in Murine Models.
Patra MC; Achek A; Kim GY; Panneerselvam S; Shin HJ; Baek WY; Lee WH; Sung J; Jeong U; Cho EY; Kim W; Kim E; Suh CH; Choi S
Cells; 2020 Jul; 9(7):. PubMed ID: 32660060
[TBL] [Abstract][Full Text] [Related]
9. Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.
Lai CY; Su YW; Lin KI; Hsu LC; Chuang TH
J Immunol Res; 2017; 2017():7807313. PubMed ID: 28894754
[TBL] [Abstract][Full Text] [Related]
10. Virtual Screening Approaches towards the Discovery of Toll-Like Receptor Modulators.
Pérez-Regidor L; Zarioh M; Ortega L; Martín-Santamaría S
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618029
[TBL] [Abstract][Full Text] [Related]
11. Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics.
Gomariz RP; Gutiérrez-Cañas I; Arranz A; Carrión M; Juarranz Y; Leceta J; Martínez C
Curr Pharm Des; 2010; 16(9):1063-80. PubMed ID: 20030612
[TBL] [Abstract][Full Text] [Related]
12. TLR activation pathways in HIV-1-exposed seronegative individuals.
Biasin M; Piacentini L; Lo Caputo S; Naddeo V; Pierotti P; Borelli M; Trabattoni D; Mazzotta F; Shearer GM; Clerici M
J Immunol; 2010 Mar; 184(5):2710-7. PubMed ID: 20124101
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptors: potential targets for lupus treatment.
Wu YW; Tang W; Zuo JP
Acta Pharmacol Sin; 2015 Dec; 36(12):1395-407. PubMed ID: 26592511
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptors and their role in hematologic malignancies.
Wolska A; Lech-Maranda E; Robak T
Curr Mol Med; 2009 Apr; 9(3):324-35. PubMed ID: 19355914
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics.
Gao W; Xiong Y; Li Q; Yang H
Front Physiol; 2017; 8():508. PubMed ID: 28769820
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives.
Mukherjee S; Patra R; Behzadi P; Masotti A; Paolini A; Sarshar M
Front Immunol; 2023; 14():1244345. PubMed ID: 37822929
[TBL] [Abstract][Full Text] [Related]
17. Toll-like Receptors as a Novel Therapeutic Target for Natural Products Against Chronic Diseases.
Narayanankutty A
Curr Drug Targets; 2019; 20(10):1068-1080. PubMed ID: 30806312
[TBL] [Abstract][Full Text] [Related]
18. A peptide derived from the core β-sheet region of TIRAP decoys TLR4 and reduces inflammatory and autoimmune symptoms in murine models.
Achek A; Kwon HK; Patra MC; Shah M; Hong R; Lee WH; Baek WY; Choi YS; Kim GY; Pham TLH; Suh CH; Kim W; Hahm DH; Choi S
EBioMedicine; 2020 Feb; 52():102645. PubMed ID: 32014819
[TBL] [Abstract][Full Text] [Related]
19. The role of Toll-like receptors in multiple sclerosis and possible targeting for therapeutic purposes.
Gooshe M; Abdolghaffari AH; Gambuzza ME; Rezaei N
Rev Neurosci; 2014; 25(5):713-39. PubMed ID: 24914714
[TBL] [Abstract][Full Text] [Related]
20. Balancing Inflammation: Computational Design of Small-Molecule Toll-like Receptor Modulators.
Murgueitio MS; Rakers C; Frank A; Wolber G
Trends Pharmacol Sci; 2017 Feb; 38(2):155-168. PubMed ID: 27863853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
